MX2020012964A - Metodos para el tratamiento de cancer de vejiga. - Google Patents
Metodos para el tratamiento de cancer de vejiga.Info
- Publication number
- MX2020012964A MX2020012964A MX2020012964A MX2020012964A MX2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A MX 2020012964 A MX2020012964 A MX 2020012964A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- bladder cancer
- bladder
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
En la presente se proporcionan métodos para el tratamiento de cáncer de vejiga.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862679495P | 2018-06-01 | 2018-06-01 | |
US201962826347P | 2019-03-29 | 2019-03-29 | |
PCT/US2019/034933 WO2019232392A1 (en) | 2018-06-01 | 2019-05-31 | Methods for the treatment of bladder cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012964A true MX2020012964A (es) | 2021-02-16 |
Family
ID=67138025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012964A MX2020012964A (es) | 2018-06-01 | 2019-05-31 | Metodos para el tratamiento de cancer de vejiga. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210205348A1 (es) |
EP (1) | EP3801561A1 (es) |
JP (1) | JP7335277B2 (es) |
KR (1) | KR20210015937A (es) |
CN (1) | CN112512531B (es) |
AU (1) | AU2019277679A1 (es) |
BR (1) | BR112020024605A2 (es) |
CA (1) | CA3101623A1 (es) |
MX (1) | MX2020012964A (es) |
SG (1) | SG11202011434SA (es) |
WO (1) | WO2019232392A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
WO2023039363A1 (en) | 2021-09-09 | 2023-03-16 | Eisai R&D Management Co., Ltd. | Biomarkers for sting agonists and methods of using the same |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
BR112015013440B1 (pt) | 2012-12-13 | 2020-12-08 | Aduro Biotech, Inc | composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas |
WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
EP3071209A4 (en) * | 2013-11-19 | 2017-08-16 | The University of Chicago | Use of sting agonist as cancer treatment |
US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
PE20170198A1 (es) | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
EP3546473A1 (en) | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
CN107106589A (zh) | 2014-12-17 | 2017-08-29 | 立博美华基因科技有限责任公司 | 用cGAMP或cGAsMP治疗癌症的方法 |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
WO2017027645A1 (en) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
RU2020113165A (ru) | 2015-12-03 | 2020-06-09 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | タンパク質調節物質として有用な複素環アミド |
JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
RU2020112502A (ru) | 2017-08-30 | 2021-10-01 | Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона |
JP7208225B2 (ja) | 2017-08-31 | 2023-01-18 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
JP7316263B2 (ja) | 2017-08-31 | 2023-07-27 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
-
2019
- 2019-05-31 EP EP19734956.6A patent/EP3801561A1/en active Pending
- 2019-05-31 KR KR1020207037794A patent/KR20210015937A/ko active Search and Examination
- 2019-05-31 CA CA3101623A patent/CA3101623A1/en active Pending
- 2019-05-31 AU AU2019277679A patent/AU2019277679A1/en active Pending
- 2019-05-31 SG SG11202011434SA patent/SG11202011434SA/en unknown
- 2019-05-31 CN CN201980050644.2A patent/CN112512531B/zh active Active
- 2019-05-31 BR BR112020024605-0A patent/BR112020024605A2/pt unknown
- 2019-05-31 US US17/058,817 patent/US20210205348A1/en active Pending
- 2019-05-31 MX MX2020012964A patent/MX2020012964A/es unknown
- 2019-05-31 WO PCT/US2019/034933 patent/WO2019232392A1/en unknown
- 2019-05-31 JP JP2020566898A patent/JP7335277B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7335277B2 (ja) | 2023-08-29 |
EP3801561A1 (en) | 2021-04-14 |
CN112512531B (zh) | 2024-04-09 |
AU2019277679A1 (en) | 2020-12-24 |
BR112020024605A2 (pt) | 2021-04-06 |
SG11202011434SA (en) | 2020-12-30 |
CA3101623A1 (en) | 2019-12-05 |
KR20210015937A (ko) | 2021-02-10 |
CN112512531A (zh) | 2021-03-16 |
WO2019232392A1 (en) | 2019-12-05 |
US20210205348A1 (en) | 2021-07-08 |
JP2021525758A (ja) | 2021-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA193736S (en) | Skin massager | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
ECSP17073743A (es) | Moduladores de k-ras | |
WO2018136617A3 (en) | Bacteria for treating cancer | |
EP3565558A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
EP3610026A4 (en) | BLADDER CANCER TREATMENT METHODS | |
EA201991818A1 (ru) | Лечение рака | |
GB201903546D0 (en) | Cancer treatment | |
IL281845A (en) | Combined treatment for cancer | |
IL282093A (en) | Combination therapy for cancer | |
EP3713576A4 (en) | CANCER TREATMENT METHODS | |
IL287652A (en) | Cancer treatment | |
IL284162A (en) | Integrated healing for cancer treatment | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
IL285466A (en) | Cancer treatment | |
MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
IL288035A (en) | Cancer treatment | |
GB201819920D0 (en) | Cancer treatment | |
GB201910644D0 (en) | Cancer Treatment | |
GB201907149D0 (en) | Cancer treatment |